Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Reims – page 35

421 clinical trials in Reims, France across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Reims at a glance
421
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

421 trials in Reims

Open in trial search

Prostate cancer recurrent

Not recruiting

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer AG

Hidradenitis

Not recruiting

Study on the Effects and Safety of SAR442970 for Adults with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:SAR442970
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Giant cell arteritis

Not recruiting

Study on Stopping Tocilizumab for Patients with Giant Cell Arteritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Colon cancer

Not recruiting

Comparison of drug combinations containing irinotecan, oxaliplatin, fluorouracil and folinic acid for treatment of high-risk stage III colon cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Unicancer

Renal cancer metastatic

Not recruiting

Study on Cabozantinib, Nivolumab, and Ipilimumab for Patients with Advanced or Metastatic Kidney Cancer Who Have Not Received Prior Treatment

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Exelixis Inc.

Mucous membrane pemphigoid

Not recruiting

Study on Rituximab and Cyclophosphamide for Patients with Severe Mucous Membrane Pemphigoid

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Glucose
  • Sponsor:Centre Hospitalier Universitaire Rouen

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Elexacaftor
  • Sponsor:Vertex Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study on Isatuximab, Lenalidomide, and Dexamethasone for Elderly Patients with Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Centre Hospitalier Universitaire De Poitiers

Cervix carcinoma

Not recruiting

Study on Atezolizumab, Bevacizumab, and Chemotherapy for Patients with Advanced Cervical Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fundacion Grupo Espanol De Investigacion En Cancer Ginecologico

Acute myeloid leukaemia

Not recruiting

Study on Improving Survival in Acute Myeloid Leukemia for Adults Aged 18-60 Using Idarubicin, Daunorubicin, Cytarabine, and Mycophenolic Acid

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Cytarabine
  • Sponsor:Centre Hospitalier Universitaire D'Angers

Acute lymphocytic leukaemia

Not recruiting

Study on Imatinib and Chemotherapy Combination for Children with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years
  • Substances:Crisantaspase
  • Sponsor:Universita Degli Studi Di Milano Bicocca

Chronic lymphocytic leukaemia+1

Not recruiting

Study on Stopping and Restarting Acalabrutinib in Elderly Patients with Untreated Chronic Lymphocytic Leukemia (CLL)

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Acalabrutinib
  • Sponsor:French Innovative Leukemia Organization (F.I.L.O.).

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Reims

What the registry says about research in the country

01 Oncology Studies

Groundbreaking research exploring treatments for various cancers, including multiple myeloma, colorectal cancer, and esophageal squamous cell carcinoma. Studies focus on evaluating novel therapies and combination treatments to improve patient outcomes.

  • Advanced pancreatic adenocarcinoma treatments
  • Breast cancer therapies
  • Prostate cancer management

Several trials investigate immunotherapy approaches and targeted treatments for specific genetic mutations.

02 Autoimmune Conditions

Clinical trials examining innovative treatments for autoimmune disorders, with particular focus on rheumatoid arthritis and psoriatic conditions. Research aims to evaluate new therapeutic approaches and optimize existing treatments.

  • Plaque psoriasis treatments
  • Rheumatoid arthritis maintenance therapy
  • Gout management strategies

Studies emphasize long-term efficacy and safety profiles of various treatment regimens.

03 Transplant Medicine

Advanced research in kidney transplantation focusing on preventing rejection and improving long-term outcomes. Studies evaluate new immunosuppressive strategies and monitoring protocols.

  • Antibody-mediated rejection prevention
  • Novel immunosuppressive protocols
  • Post-transplant monitoring techniques

Trials aim to optimize post-transplant care and reduce rejection rates.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.